Daratumumab slows progression in refractory multiple myeloma

Bookmark and Share
Published: 6 Jun 2016
Views: 1477
Prof Palumbo - University of Turin, Turin, Italy

Professor Palumbo speaks with ecancertv at ASCO 2016 about the addition of daratumumab to treatment for relapsed or refractory multiple myeloma (RRMM)

Daratumumab, the first monoclonal antibody approved for multiple myeloma, targets a protein on the surface of cancer cells called CD38.

The daratumumab combination reduced the risk of cancer progression by 70%, and doubled both very good partial response rates from 29% to 59% and complete response rates from 9% to 19%.

More details on the CASTOR study were featured in the press announcement, available here.